Abstract:
A composition for imaging a biological tissue or fluid comprising a compound of formula (A) and a biologically acceptable diluent or carrier, (A) wherein X represents one of a nitrogen atom, an oxygen atom, a sulphur atom, a phosphorus atom, or a selenium atom; R represents an aromatic group and/or an aliphatic group; p is an integer of 1 to 2; q and s are independently integers of 1, 2, 3, or 4; Y1, Y2, and Y3 independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a polyglycol group, an oxygen atom, a nitrogen atom, a cyano group, a nitro group; and/or wherein two or more of Y1, Y2, and Y3 may combine together to form a condensed ring.
Abstract:
Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
Abstract:
This invention relates to known and novel hydroxyquinolin-2(1 H )-ones and derivatives thereof which are useful for the treatment of cognitive-related disorders and neuropathic pain disorders in a mammal, e.g., a human. The invention also relates to pharmaceutical compositions containing such compounds.
Abstract:
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g. a hydrate), or a pharmaceutically-acceptable salt, thereof, wherein: M is selected from alkyl, substituted alkyl, cycloalkyl, aryl, heterocyclo, and heteroaryl, provided that if M is alkyl then R 6 and R 7 taken together with the carbon atom to which they are both attached are selected from a group other than cycloalkyl; Q is selected from (i) hydrogen, C 1 -C 4 alkyl, and substituted C 1 -C 4 alkyl; or (ii) Q and R 6 are combined with the carbon atoms to which they are attached to form a 3- to 6-membered cycloalkyl; or (iii) Q and M a M are combined with the carbon atom(s) to which they are attached to form a 3- to 7-membered ring containing 1-2 heteroatoms which are independently selected from the group consisting of O, S, SO 2 , and N which ring may be optionally substituted with 0-2 R 5 groups or carbonyl; Z is selected from cycloalkyl, heterocyclo, aryl, or heteroaryl; and M a , Z a , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 22 are as defined herein. Also provided are pharmaceutical compositions and methods of treating metabolic and inflammatory- or immune-associated diseases or disorders using said compounds.
Abstract translation:提供了新颖的非类固醇化合物,其用于治疗与糖皮质激素受体,AP-1和/或NF-κB活性的调节相关的疾病,包括具有式(I)结构的炎性和免疫疾病,肥胖症和糖尿病, 其中:M选自烷基,取代的烷基,环烷基,芳基,杂环基和杂芳基,条件是如果M是烷基,则M是烷基,取代的烷基,环烷基, R 6和R 7与它们都连接的碳原子一起选自除环烷基以外的基团; Q选自(i)氢,C 1 -C 4烷基和取代的C 1 -C 4 SUB SUB> 烷基; 或(ii)Q和R 6与它们所连接的碳原子结合形成3至6元环烷基; 或(iii)Q和MASS a M与它们所连接的碳原子结合形成含有1-2个独立选自以下的杂原子的3-至7-元环: 由O,S,SO 2,N和N组成的组,该环可以任选地被0-2个R 5基团或羰基取代; Z选自环烷基,杂环基,芳基或杂芳基; 和 a SUB>,Z a SUB>, 1 SUB>, 2 SUB>, 3 SUB> ,R 4,R 6,R 7,和R 22如本文所定义。 还提供了使用所述化合物治疗代谢和炎症或免疫相关疾病或病症的药物组合物和方法。
Abstract:
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
Abstract:
The present invention relates to azabicyclic ring ammoniums of general formula I in which the definition of each radical is described in the specification and/or their pharmaceutically acceptable salts and hydrates; pharmaceutical compositions comprising the same, also to the uses of those compositions for the preparation of medicaments for (i) improving the elasticity or reducing wrinkles of the skin, (ii) treating diabetes, (iii) treating or ameliorating adverse sequelae of diabetes, (iv) treating or ameliorating kidney damage, (v) treating or ameliorating blood vasculature, (vi) treating or ameliorating hypertension, (vii) treating or ameliorating retinopathy, (viii) treating or ameliorating damage to lens proteins, (ix) treating or ameliorating cataracts, (x) treading or ameliorating peripheral neuropathy, (xi) treating or ameliorating osteoarthritis, or use for the preparation of a buccal medicament for preventing or reversing the staining of teeth, or the use for the preparation of various freshness keeper for crops plant protein, animal protein.
Abstract:
In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue fissuion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.
Abstract:
A cyanine dye having formula (II), wherein R1-R8 are each independently selected from a group consisting of hydrogen, C1-C6 alkyl group, and C0-C4 alkyl group having a hydrophilic substituent thereon. R11 and R12 are chosen to include a free or protected thiol, amine or hydroxyl substituent capable of reacting with a target molecule through a nucleophilic displacement mechanism. The dye is useful in labeling a variety of target molecules. Processes are described for synthesizing suitable heterocyclic and indole derivatives as precursors for the aforementioned cyanine dyes.
Abstract:
The invention relates to polycyclic thiazolidin-2-ylidene amines and the physiologically acceptable salts and physiologically functional derivatives thereof. Disclosed are polycyclic thiazolidin-2-ylidene amines of formula (I), wherein the radicals mentioned have the meanings as cited. The invention also relates to the physiologically acceptable salts and to a method of production thereof. The compounds can be used as anoretics.